Kestra Medical Applied sciences, Ltd. (KMTS) Q3 2026 Earnings Name March 17, 2026 4:30 PM EDT
Firm Individuals
Neil Bhalodkar – Vice President of Investor Relations
Brian Webster – Founder, President, CEO & Director
Vaseem Mahboob – Chief Monetary Officer
Convention Name Individuals
Travis Steed – BofA Securities, Analysis Division
Matthew O’Brien – Piper Sandler & Co., Analysis Division
Nathan Treybeck – Wells Fargo Securities, LLC, Analysis Division
Michael Polark – Wolfe Analysis, LLC
Frederick Smart – Stifel, Nicolaus & Firm, Included, Analysis Division
Marie Thibault – BTIG, LLC, Analysis Division
David Roman – Goldman Sachs Group, Inc., Analysis Division
Presentation
Operator
Good afternoon, and welcome to Kestra Medical Applied sciences Earnings Convention Name. This convention name is being recorded for replay functions. We shall be facilitating a question-and-answer session following ready remarks from administration. Presently, all individuals are in listen-only mode.
I might now like to show the decision over to Neil Bhalodkar, Vice President of Investor Relations for introductory feedback.
Neil Bhalodkar
Vice President of Investor Relations
Thanks, Victor. Good afternoon. Thanks for becoming a member of Kestra’s Third Quarter Fiscal 2026 Earnings Name. With me at the moment are Brian Webster, President and Chief Govt Officer; and Vaseem Mahboob, Chief Monetary Officer.
This name consists of forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. Statements made on this name that don’t relate to issues of historic truth needs to be thought of forward-looking statements. These statements are based mostly on Kestra’s present expectations, forecasts and assumptions, that are topic to inherent uncertainties, dangers and assumptions which might be troublesome to foretell.
Precise outcomes and outcomes may differ materially from any outcomes, efficiency or achievements expressed or implied by the forward-looking statements on account of numerous elements. Please assessment Kestra’s most up-to-date filings with the SEC significantly the chance elements described in our Type 10-Okay, for added data.
